This bill introduces a new section to RSA 420-B that mandates health maintenance organizations (HMOs) to utilize the lowest cost method for reimbursing clinician-administered drugs. It defines "clinician-administered drugs" as outpatient prescription drugs that cannot be reasonably self-administered and are typically administered by a healthcare professional in clinical settings. The bill also requires HMOs to cover these drugs if they are dispensed by in-network hospitals or clinics, provided that the medication is needed more urgently than through other covered channels.

Additionally, the bill prohibits HMOs from requiring pharmacies to dispense clinician-administered drugs directly to patients with the expectation that they will transport the medication to a healthcare setting for administration. This practice, known as "brown-bagging," is seen as potentially increasing costs for insurers and patients. The bill is set to take effect on January 1, 2026, and does not provide funding or authorize new positions, with the fiscal impact on state revenue being indeterminable.